Affiliation:
1. TeraPore Technologies South San Francisco California USA
2. Department of Chemical Engineering McMaster University Hamilton Ontario Canada
Abstract
AbstractMembrane fouling by monoclonal antibodies (mAbs) is one of the main challenges in virus‐filtration processes. Previous publications attributed membrane fouling to the presence of mAb aggregates in the solution, which block the membrane pores. This fouling mechanism can be solved by a prefilter; however, it was shown that there are mAbs that severely foul the membranes (reduce permeability by 90% and more) even after prefiltering the aggregates, while other mAbs foul the membrane weakly (reduce permeability by ~10% and less). Unfortunately, the differences between the fouling‐ and the nonfouling mAbs have never been convincingly explained. To get a deeper insight on these differences, we measured the fouling of chemically modified Isoprene‐Styrene‐4‐vinylpyridine (ISV) membranes (TeraPore Technologies) by 8 mAbs exhibiting different hydrophobicity and charge. The results show that mAb solutions with low concentration of aggregates foul ISV membranes via an adsorptive mechanism, and the adsorption is driven mainly by hydrophobic forces between the mAb and the membrane. The charge of the mAbs plays a secondary role in fouling. We want to emphasize that the conclusions pertain to ISV membranes; the insights presented in this paper can potentially be used to engineer new surface chemistries to mitigate fouling of other virus‐filtration and/or ultrafiltration membranes.
Subject
Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference31 articles.
1. Bak H.(2022).Precision medicine for cancer treatment leveraging industrialized robust and simple bispecific antibody platform: Learnings from a 10‐year journey presented at the recovery conference July 11.
2. Investigation of fouling mechanisms of virus filters during the filtration of protein solutions using a high throughput filtration screening device
3. Blankenship K.(2019). The top 20 drugs by 2018 U.S. Sales.https://www.fiercepharma.com/special-report/top-20-drugs-by-2018-u-s-sales
4. Blankenship K.(2020). The top 20 drugs by 2018 U.S. Sales.https://www.fiercepharma.com/special-report/top-20-drugs-by-2018-u-s-sales
5. Increasing the capacity of parvovirus-retentive membranes: performance of the Viresolve™ Prefilter
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献